JP2018171062A5 - - Google Patents

Download PDF

Info

Publication number
JP2018171062A5
JP2018171062A5 JP2018109490A JP2018109490A JP2018171062A5 JP 2018171062 A5 JP2018171062 A5 JP 2018171062A5 JP 2018109490 A JP2018109490 A JP 2018109490A JP 2018109490 A JP2018109490 A JP 2018109490A JP 2018171062 A5 JP2018171062 A5 JP 2018171062A5
Authority
JP
Japan
Prior art keywords
cell population
test
cancer cells
domain peptide
contacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018109490A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018171062A (ja
JP6684857B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018171062A publication Critical patent/JP2018171062A/ja
Publication of JP2018171062A5 publication Critical patent/JP2018171062A5/ja
Application granted granted Critical
Publication of JP6684857B2 publication Critical patent/JP6684857B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018109490A 2012-09-19 2018-06-07 ダイナミックｂｈ３プロファイリング Active JP6684857B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261702967P 2012-09-19 2012-09-19
US61/702,967 2012-09-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015533194A Division JP6352924B2 (ja) 2012-09-19 2013-09-19 ダイナミックｂｈ３プロファイリング

Publications (3)

Publication Number Publication Date
JP2018171062A JP2018171062A (ja) 2018-11-08
JP2018171062A5 true JP2018171062A5 (cg-RX-API-DMAC7.html) 2018-12-20
JP6684857B2 JP6684857B2 (ja) 2020-04-22

Family

ID=49304346

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015533194A Active JP6352924B2 (ja) 2012-09-19 2013-09-19 ダイナミックｂｈ３プロファイリング
JP2018109490A Active JP6684857B2 (ja) 2012-09-19 2018-06-07 ダイナミックｂｈ３プロファイリング

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015533194A Active JP6352924B2 (ja) 2012-09-19 2013-09-19 ダイナミックｂｈ３プロファイリング

Country Status (7)

Country Link
US (2) US10393733B2 (cg-RX-API-DMAC7.html)
EP (1) EP2898327A1 (cg-RX-API-DMAC7.html)
JP (2) JP6352924B2 (cg-RX-API-DMAC7.html)
AU (1) AU2013317985B2 (cg-RX-API-DMAC7.html)
CA (1) CA2885230C (cg-RX-API-DMAC7.html)
HK (1) HK1213046A1 (cg-RX-API-DMAC7.html)
WO (1) WO2014047342A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006516383A (ja) 2002-09-09 2006-07-06 デイナ−ファーバー キャンサー インスティチュート，インコーポレイテッド Ｂｈ３ペプチドおよびその使用方法
EP2008106A2 (en) 2006-03-31 2008-12-31 Dana-Farber Cancer Institute Methods of determining cellular chemosensitivity
CA2885230C (en) 2012-09-19 2021-08-03 Anthony Letai Dynamic bh3 profiling
EP3022222A4 (en) * 2013-07-18 2017-06-07 Eutropics Pharmaceuticals, Inc. Differential bh3 mitochondrial profiling
EP3047276B1 (en) 2013-09-19 2023-06-14 Dana-Farber Cancer Institute, Inc. Methods of bh3 profiling
WO2016115105A1 (en) 2015-01-12 2016-07-21 Eutropics Pharmaceuticals, Inc. Context dependent diagnostics test for guiding cancer treatment
WO2016154380A1 (en) * 2015-03-24 2016-09-29 Eutropics Pharmaceuticals, Inc. Surrogate functional biomarker for solid tumor cancer
BR112017022666A8 (pt) 2015-04-20 2022-10-18 Tolero Pharmaceuticals Inc Preparando resposta à alvocidib por perfilamento mitocondrial
US10761086B2 (en) * 2015-04-27 2020-09-01 Dana-Farber Cancer Institute, Inc. High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells
TR201911032T4 (tr) 2015-05-18 2019-08-21 Tolero Pharmaceuticals Inc Artırılmış biyoyararlanıma sahip alvocıdıb ön ilaçları.
JP7083497B2 (ja) 2015-08-03 2022-06-13 スミトモ ファーマ オンコロジー， インコーポレイテッド がんの処置のための併用療法
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
CN110234659A (zh) 2016-12-19 2019-09-13 特雷罗药物股份有限公司 用于敏感性分析的分析肽和方法
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
EP3385715A1 (en) 2017-04-04 2018-10-10 Medizinische Hochschule Hannover Analytical process for predicting the therapeutic effect of bh3 mimetics
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
KR20210099066A (ko) 2018-12-04 2021-08-11 스미토모 다이니폰 파마 온콜로지, 인크. 암의 치료를 위한 작용제로서 사용하기 위한 cdk9 억제제 및 그의 다형체
EP3931563A4 (en) * 2019-02-26 2022-12-21 Dana-Farber Cancer Institute, Inc. Live cell imaging dynamic bh3 profiling
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
EP4306953A1 (en) 2022-07-12 2024-01-17 Fundació Institut de Bioenginyeria de Catalunya (IBEC) Real-time tracking of apoptosis

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU641673B2 (en) 1989-06-29 1993-09-30 Medarex, Inc. Bispecific reagents for aids therapy
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5674980A (en) 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ATE381614T1 (de) 1992-07-24 2008-01-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AU5632296A (en) 1995-04-27 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
BR9610058A (pt) 1995-07-28 1999-07-27 Marie Curie Cancer Care Uso de vp22 ou uma porção ativa fragmento ou homólogo do mesmo proteína de transporte ácido nucleíco vetor de expressão célula hospedeira de mamíferos ou microbiana e processos para transportar uma proteína ou peptídeo desejado para uma população de marcaç o de células e para transportar uma molécula desejada em uma população de células
WO1997015831A1 (en) 1995-10-24 1997-05-01 Sangstat Medical Corporation Anti alpha-galactosyl screening technique
US5965703A (en) 1996-09-20 1999-10-12 Idun Pharmaceuticals Human bad polypeptides, encoding nucleic acids and methods of use
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US7064193B1 (en) 1997-09-17 2006-06-20 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
WO2000059526A1 (en) 1999-04-07 2000-10-12 Thomas Jefferson University Enhancement of peptide cellular uptake
AU6906100A (en) 1999-08-16 2001-03-13 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Receptor-mediated uptake of an extracellular bcl-xl fusion protein inhibits apoptosis
WO2002020568A2 (en) 2000-09-06 2002-03-14 Abbott Laboratories Mutant peptides derived from bad and their use to identify substances which bind to a member of the bcl-2 family of proteins
AU2002258399A1 (en) 2001-02-16 2002-09-19 Medical College Of Georgia Research Institute, Inc. Use of trail and antiprogestins for treating cancer
WO2003040168A2 (en) 2001-11-06 2003-05-15 Enanta Pharmaceuticals, Inc. Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype
EP1455819A1 (en) 2001-12-21 2004-09-15 Arius Research, Inc. Individualized anti-cancer antibodies
JP2006516383A (ja) 2002-09-09 2006-07-06 デイナ−ファーバー キャンサー インスティチュート，インコーポレイテッド Ｂｈ３ペプチドおよびその使用方法
WO2004058804A1 (en) 2002-12-24 2004-07-15 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
AU2004221348A1 (en) 2003-03-19 2004-09-30 Alfa Wassermann, Inc. Separation and accumulation of subcellular components, and proteins derived therefrom
CA2830063C (en) 2003-11-05 2017-10-31 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
WO2006069186A2 (en) * 2004-12-22 2006-06-29 The Ohio State Research Foundation Small molecule bcl-xl/bcl-2 binding inhibitors
JP2005130867A (ja) 2005-02-16 2005-05-26 Mitokor ミトコンドリア内カルシウムを使用するスクリーニングアッセイ
WO2006099667A1 (en) 2005-03-21 2006-09-28 The Walter And Eliza Hall Institute Of Medical Research Prophylactic and therapeutic agents and uses therefor
WO2007016254A2 (en) 2005-07-27 2007-02-08 The Board Of Trustees Of The University Of Arkansas Antineoplastic activities of ellipticine and its derivatives
EP2008106A2 (en) * 2006-03-31 2008-12-31 Dana-Farber Cancer Institute Methods of determining cellular chemosensitivity
US8518635B2 (en) 2006-06-12 2013-08-27 The J. David Gladstone Institutes Regulation of protein activity by reversible acetylation
KR100786759B1 (ko) 2006-07-07 2007-12-18 김현기 Ｈｃｃｒ-1을 포함하는 유방암 예후 마커 및 비만 유도조성물
US9360473B2 (en) * 2006-08-16 2016-06-07 Eutropics Pharmaceuticals, Inc. Assay system to identify therapeutic agents
WO2008152405A2 (en) 2007-06-15 2008-12-18 The Queen's University Of Belfast Protein complexes comprising bh3 peptides and voltage dependent anion channel (vdac) peptides as well as uses thereof for the treatment of proliferative diseases
CN101854955B (zh) 2007-09-10 2012-07-18 马萨诸塞大学 靶向线粒体的抗肿瘤剂
WO2009042237A2 (en) 2007-09-26 2009-04-02 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
JP2009240173A (ja) 2008-03-28 2009-10-22 Univ Of Tokushima パーキン蛋白の新規糖化因子
KR20170075023A (ko) 2009-06-11 2017-06-30 미네르바 바이오테크놀로지 코포레이션 줄기 세포 및 전구 세포를 배양하는 방법
WO2010147961A1 (en) 2009-06-15 2010-12-23 Precision Therapeutics, Inc. Methods and markers for predicting responses to chemotherapy
US20130122492A1 (en) 2011-11-14 2013-05-16 Kellbenx Inc. Detection, isolation and analysis of rare cells in biological fluids
EP3236262B1 (en) * 2012-05-10 2019-09-25 Eutropics Pharmaceuticals, Inc. Surrogate functional diagnostics test for cancer
WO2013188978A1 (en) 2012-06-20 2013-12-27 Cytospan Technologies Corporation Apparatus and method for quantification of replicative lifespan and observation of senescene
CA2885230C (en) 2012-09-19 2021-08-03 Anthony Letai Dynamic bh3 profiling
JP6327662B2 (ja) 2012-09-26 2018-05-23 学校法人藤田学園 細胞表面タンパクを抗原とする抗体を測定する方法
EP3022222A4 (en) 2013-07-18 2017-06-07 Eutropics Pharmaceuticals, Inc. Differential bh3 mitochondrial profiling
EP3047276B1 (en) 2013-09-19 2023-06-14 Dana-Farber Cancer Institute, Inc. Methods of bh3 profiling
US10761086B2 (en) 2015-04-27 2020-09-01 Dana-Farber Cancer Institute, Inc. High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells
US11092602B2 (en) 2015-07-06 2021-08-17 Whitehead Institute For Biomedical Research Methods and compositions relating to proteasome inhibitor resistance
EP3931563A4 (en) 2019-02-26 2022-12-21 Dana-Farber Cancer Institute, Inc. Live cell imaging dynamic bh3 profiling

Similar Documents

Publication Publication Date Title
JP2018171062A5 (cg-RX-API-DMAC7.html)
Doyle et al. Nuclear expression of CAMTA1 distinguishes epithelioid hemangioendothelioma from histologic mimics
Brady et al. ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway
Hu et al. Epithelial‐mesenchymal transition may be involved in the immune evasion of circulating gastric tumor cells via downregulation of ULBP1
Stella et al. MET mutations in cancers of unknown primary origin (CUPs)
El Makarem An overview of biomarkers for the diagnosis of hepatocellular carcinoma
JP2015531606A5 (cg-RX-API-DMAC7.html)
EP3755816B1 (en) Methods for prostate cancer detection and treatment
Thway et al. Rhabdoid variant of myoepithelial carcinoma, with EWSR1 rearrangement: expanding the spectrum of EWSR1-rearranged myoepithelial tumors
Freier et al. Immunohistochemical evaluation of the role of p53 mutation in cervical cancer: Ser-20 p53-mutant correlates with better prognosis
Yuminamochi et al. Expression of the LIM proteins paxillin and Hic-5 in human tissues
Krstic et al. KLF4 expression and apoptosis-related markers in gastric cancer
Liu et al. Clinical significance of EphA2 expression in squamous-cell carcinoma of the head and neck
Amsterdam et al. Differential staining of γ synuclein in poorly differentiated compared to highly differentiated colon cancer cells
Wang et al. Vasculogenic mimicry and expression of ALDH1, Beclin1, and p16 correlate with metastasis and prognosis in oral squamous cell carcinoma
Jiang et al. Differential expression and subcellular localization of Prohibitin 1 are related to tumorigenesis and progression of non-small cell lung cancer
Graveel et al. Identification and characterization of CRG-L2, a new marker for liver tumor development
Wang et al. XB130 expression in human osteosarcoma: A clinical and experimental study
Yang et al. Higher expression of Caveolin-1 inhibits human small cell lung cancer (SCLC) apoptosis in vitro
Wang et al. Clinicopathological significance of ROCK1 and PIK3CA expression in nasopharyngeal carcinoma
Lee et al. Clinical significance of GADD153 expression in stage I non-small cell lung cancer
Inoue et al. ATP7B expression is associated with in vitro sensitivity to cisplatin in non-small cell lung cancer
Comănescu et al. Cancer stem cells biomarkers in triple negative invasive carcinoma of the breast and associated in situ lesions
Hemminger et al. DOG1 (clone K9) is seldom expressed and not useful in the evaluation of pancreatic neoplasms
US7129328B2 (en) Liver tumor marker sequences